AGL:LSE-ANGLE plc (GBX)

COMMON STOCK | Diagnostics & Research | LSE

Last Closing Price

GBX 52.50

Change

-0.50 (-0.94)%

Market Cap

GBX 0.14B

Volume

0.19M

Avg Analyst Target

GBX 231.00 (+340.00%)

Avg User Target

GBX
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

AGL Stock Forecast & Price:
Based on the ANGLE plc stock forecasts from 1 analysts, the average analyst target price for ANGLE plc is GBX 231.00 over the next 12 months. ANGLE plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ANGLE plc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, ANGLE plc’s stock price was GBX 52.50. ANGLE plc’s stock price has changed by -4.55% over the past week, +0.96% over the past month and -60.97% over the last year.

About ANGLE plc (AGL:LSE)

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiple ...Read More

Company Website : https://angleplc.com

Address : Surrey Research Park, Guildford, United Kingdom, GU2 7AF

Employees : 128

Fiscal Year End : April

Currency: GBX

Country : UK

Technical Indicators

Beta : 0.74

52 Week High : 163.75

52 Week Low : 45.00

200 Day Moving Average : 81.33

50 Day Moving Average : 55.29

Shares Held By Insiders : 10.70%

Shares Held by Institutions : 27.86%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MXCL:LSE MaxCyte, Inc

N/A

 GBX0.86B N/A N/A
IDHC:LSE Integrated Diagnostics Holding..

N/A

 GBX0.44B 0.14 0.26
HZD:LSE Horizon Discovery Group plc

N/A

 GBX0.30B N/A N/A
SBI:LSE Sourcebio International PLC

N/A

 GBX0.08B 12.50 6.85
DXRX:LSE Diaceutics PLC

N/A

 GBX0.06B N/A 19.09
GENI:LSE Genincode PLC

N/A

 GBX0.04B N/A N/A
LLAI:LSE LungLife AI Inc

N/A

 GBX0.03B N/A -2.90
VRCI:LSE Verici Dx Plc

N/A

 GBX0.02B N/A -1.16
YGEN:LSE Yourgene Health PLC

N/A

 GBX0.02B N/A 14.28
PRM:LSE Proteome Sciences PLC

N/A

 GBX0.01B N/A 15.40

ETFs Containing AGL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -55.88% 50% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.88% 50% F 9% F
Trailing 12 Months  
Capital Gain -60.53% 50% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.53% 50% F 7% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 28.96% 90% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.96% 80% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 62.43% 30% F 15% F
Risk Adjusted Return 46.39% 90% A- 79% C+
Market Capitalization 0.14B 90% A- 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.50 22% F 13% F
Price / Cash Flow Ratio -10.23 100% A+ 88% B+
EV/EBITDA -6.87 100% A+ 82% B-
Management Effectiveness  
Return on Equity -55.77% 44% F 6% F
Return on Invested Capital -39.86% 50% F 5% F
Return on Assets -30.11% 40% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.74 38% F 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector